scholarly journals SAT0317 HDL-CHOLESTEROL EFFLUX CAPACITY IS DOWNREGULATED IN PATIENTS WITH SYSTEMIC SCLEROSIS.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1104.2-1104
Author(s):  
I. Ferraz-Amaro ◽  
D. F. Esmeralda ◽  
V. Hernández-Hernández ◽  
H. Sánchez-Pérez ◽  
L. De Armas-Rillo ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Systemic Sclerosis ◽  
Lipid Profile ◽  
Cholesterol Efflux ◽  
Hdl Cholesterol ◽  
Skin Thickness ◽  
Research Support ◽  
Related Data ◽  
Beta Coefficient

Background:It is well established that patients with systemic sclerosis (SS) show a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC) is the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages. CEC has been linked to cardiovascular events in the general population and to subclinical atherosclerosis in patients with rheumatoid arthritis and systemic lupus erythematosus.Objectives:The main purpose of our study was to assess, for the first time, whether CEC is disrupted in patients with SS compared to controls. We also aimed to identify patients’ characteristics that could explain such potential CEC disturbance.Methods:Cross-sectional study that encompassed 188 individuals; 73 SS patients and 115 age- and sex-matched controls. CEC, using anin vitroassay, and lipoprotein serum concentrations were assessed in patients and controls. A multivariable analysis was performed to study the differences in CEC between patients and controls, and if SS-related data could explain CEC differences.Results:CEC was downregulated in SS patients as compared to controls (beta coefficient -6 [95%CI -10- -2] %, p=0.002). This occurred independently of traditional cardiovascular risk factors, statin use or other variations in the lipid profile produced by the disease. Demographics and lipid profile were, in general, not related with CEC in both patients and controls. In this sense, only abdominal circumference showed a positive association with CEC in patients (beta coefficient 0.09 [95%CI 0.03-0.14], p=0.002) but not in controls. Similarly, no traditional cardiovascular risk factors were related with CEC in both populations. Regarding lipid profile, no correlations were identified between the standard lipid profile molecules and CEC. Remarkably, the use of statins was not related to CEC in both patients and controls. Lastly, concerning SS related data, a negative association between mRSS and CEC was identified (beta coef. -1.08 [95%CI -2.03- -0.12] %, p=0.028).Skin thickness through modified Rodnan (mRSS) was positively related to age and the presence of hypertension, but negatively associated with apolipoprotein B, apo B:A1 ratio, and CEC when univariate correlations were assessed (Table 4). When the relation of mRSS to these lipid-related molecules was adjusted for traditional CV risk factors, the statistical significance of mRSS with those molecules was maintained. Moreover, when the relation between mRSS and CEC was additionally adjusted for other lipid-related molecules, its significance was conserved (beta coef. -1.35 [95%CI -2.62- -0.08]) %, p=0.038)Conclusion:CEC is downregulated in SS patients independently of other inflammation-related lipid profile modifications that occur in the disease. Skin thickness is independent and inversely associated with CEC in SS patients.Disclosure of Interests:Iván Ferraz-Amaro Grant/research support from: Pfizer, Abbvie, Speakers bureau: Pfizer, Abbvie, MSD., delgado frias esmeralda Speakers bureau: Pfizer, Abbvie, MSD, Vanessa Hernández-Hernández Speakers bureau: Pfizer, Abbvie, MSD, Hiurma Sánchez-Pérez: None declared, Laura de Armas-Rillo: None declared, Estefania Armas González: None declared, Jose David Machado: None declared, Federico Díaz-González Grant/research support from: Abbvie, Pfizer, MSD, Speakers bureau: Abbvie, Pfizer, MSD

scholarly journals HDL-Cholesterol Efflux Capacity and Lipid Profile in Patients with Systemic Sclerosis.

2020 ◽  
Author(s):  
Iván Ferraz-Amaro ◽  
Esmeralda Delgado-Frías ◽  
Vanesa Hernández-Hernández ◽  
Hiurma Sánchez-Pérez ◽  
Laura de Armas-Rillo ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Systemic Sclerosis ◽  
Lipid Profile ◽  
Cholesterol Efflux ◽  
Hdl Cholesterol ◽  
Skin Thickness ◽  
Vitro Assay ◽  
Cholesterol Efflux Capacity ◽  
Related Data ◽  
Beta Coefficient

Abstract Objective. It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages has been linked to cardiovascular events. The aim of this study was to establish whether CEC and lipid profile were impaired in SSc patients respect to controls and whether these changes were associated with disease-related data. Methods. Cross-sectional study encompassed 188 individuals: 73 SSc patients and 115 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. A multivariable analysis was performed to study the differences in CEC between patients and controls, and if SSc-related data could explain such differences. Results. The multivariate analysis adjusted for demographic characteristics, cardiovascular risk factors and lipid-related molecules showed that total cholesterol (beta coefficient: -22 [95%CI -37- -7], p=0.004), triglycerides (beta coefficient: 24 [95%CI 2-47], p=0.033), lipoprotein A (beta coefficient: 22 [95%CI 2-43], p=0.033) and CEC (beta coefficient: -6 [95%CI -10- -2]%,p=0.002) were significantly differences between patients and controls. Skin thickness, as assessed by modified Rodnan skin score, was independently associated with a lower CEC (beta coefficient: -0.21 [95%CI -0.37- -0.05]%, p=0.011) after multivariable adjustment. Conclusion. SSc patients show an abnormal lipid profile with respect to controls including CEC. Skin thickness is independent and inversely associated with CEC in SSc patients.

scholarly journals HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Iván Ferraz-Amaro ◽  
Esmeralda Delgado-Frías ◽  
Vanesa Hernández-Hernández ◽  
Hiurma Sánchez-Pérez ◽  
Laura de Armas-Rillo ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Systemic Sclerosis ◽  
Lipid Profile ◽  
Cholesterol Efflux ◽  
Multivariable Analysis ◽  
Hdl Cholesterol ◽  
Skin Thickness ◽  
Cholesterol Efflux Capacity ◽  
Related Data ◽  
Beta Coefficient

Abstract Objective It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages, has been linked to cardiovascular events. The aim of this study was to establish whether CEC and lipid profile were impaired in SSc patients with respect to controls and whether these changes were associated with disease-related data. Methods Cross-sectional study encompassed 188 individuals: 73 SSc patients and 115 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. A multivariable analysis was performed to study the differences in CEC between patients and controls, and if SSc-related data could explain such differences. Results The multivariable analysis adjusted for demographic characteristics, cardiovascular risk factors, and lipid-related molecules showed that total cholesterol (beta coefficient: − 22 [95%CI – 37 to – 7], p = 0.004), triglycerides (beta coefficient: 24 [95%CI 2–47], p = 0.033), lipoprotein A (beta coefficient: 22 [95%CI 2–43], p = 0.033), and CEC (beta coefficient: – 6 [95%CI − 10 to – 2]%,p = 0.002) were significantly different between patients and controls. Skin thickness, as assessed by modified Rodnan skin score, was independently associated with a lower CEC (beta coefficient: – 0.21 [95%CI – 0.37 to – 0.05]%, p = 0.011) after multivariable adjustment. Conclusion SSc patients show an abnormal lipid profile with respect to controls including CEC. Skin thickness is independent and inversely associated with CEC in SSc patients.

scholarly journals HDL-Cholesterol Efflux Capacity and Lipid Profile in Patients With Systemic Sclerosis

2020 ◽  
Author(s):  
Iván Ferraz-Amaro ◽  
Esmeralda Delgado-Frías ◽  
Vanesa Hernández-Hernández ◽  
Hiurma Sánchez-Pérez ◽  
Laura de Armas-Rillo ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Systemic Sclerosis ◽  
Lipid Profile ◽  
Cholesterol Efflux ◽  
Hdl Cholesterol ◽  
Skin Thickness ◽  
Vitro Assay ◽  
Cholesterol Efflux Capacity ◽  
Related Data ◽  
Beta Coefficient

Abstract Objective. It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages has been linked to cardiovascular events. The aim of this study was to establish whether CEC and lipid profile were impaired in SSc patients respect to controls and whether these changes were associated with disease-related data.Methods. Cross-sectional study encompassed 188 individuals: 73 SSc patients and 115 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. A multivariable analysis was performed to study the differences in CEC between patients and controls, and if SSc-related data could explain such differences. Results. The multivariate analysis adjusted for demographic characteristics, cardiovascular risk factors and lipid-related molecules showed that total cholesterol (beta coefficient: -22 [95%CI -37- -7], p=0.004), triglycerides (beta coefficient: 24 [95%CI 2-47], p=0.033), lipoprotein A (beta coefficient: 22 [95%CI 2-43], p=0.033) and CEC (beta coefficient: -6 [95%CI -10- -2]%,p=0.002) were significantly differences between patients and controls. Skin thickness, as assessed by modified Rodnan skin score, was independently associated with a lower CEC (beta coefficient: -0.21 [95%CI -0.37- -0.05]%, p=0.011) after multivariable adjustment.Conclusion: SSc patients show an abnormal lipid profile respect to controls including CEC, a finding that could be involved in the increased cardiovascular burden suffered by these patients. Skin thickness is independent and inversely associated with CEC in SSc patients.

scholarly journals HDL-Cholesterol Efflux Capacity and Lipid Profile in Patients with Systemic Sclerosis.

2021 ◽  
Author(s):  
Iván Ferraz-Amaro ◽  
Esmeralda Delgado-Frías ◽  
Vanesa Hernández-Hernández ◽  
Hiurma Sánchez-Pérez ◽  
Laura de Armas-Rillo ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Systemic Sclerosis ◽  
Lipid Profile ◽  
Cholesterol Efflux ◽  
Multivariable Analysis ◽  
Hdl Cholesterol ◽  
Skin Thickness ◽  
Cholesterol Efflux Capacity ◽  
Related Data ◽  
Beta Coefficient

Abstract Objective. It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages has been linked to cardiovascular events. The aim of this study was to establish whether CEC and lipid profile were impaired in SSc patients respect to controls and whether these changes were associated with disease-related data.Methods. Cross-sectional study encompassed 188 individuals: 73 SSc patients and 115 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. A multivariable analysis was performed to study the differences in CEC between patients and controls, and if SSc-related data could explain such differences. Results. The multivariable analysis adjusted for demographic characteristics, cardiovascular risk factors and lipid-related molecules showed that total cholesterol (beta coefficient: -22 [95%CI -37- -7], p=0.004), triglycerides (beta coefficient: 24 [95%CI 2-47], p=0.033), lipoprotein A (beta coefficient: 22 [95%CI 2-43], p=0.033) and CEC (beta coefficient: -6 [95%CI -10- -2]%,p=0.002) were significantly differences between patients and controls. Skin thickness, as assessed by modified Rodnan skin score, was independently associated with a lower CEC (beta coefficient: -0.21 [95%CI -0.37- -0.05]%, p=0.011) after multivariable adjustment.Conclusion: SSc patients show an abnormal lipid profile with respect to controls including CEC. Skin thickness is independent and inversely associated with CEC in SSc patients.

Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis

Rheumatology ◽  
2020 ◽  
Vol 59 (10) ◽  
pp. 2847-2856 ◽  
Author(s):  
Hiurma Sánchez-Pérez ◽  
Juan Carlos Quevedo-Abeledo ◽  
Laura de Armas-Rillo ◽  
Íñigo  Rua--Figueroa ◽  
Beatriz Tejera-Segura ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Lipid Profile ◽  
Cardiovascular Risk Factors ◽  
Cholesterol Efflux ◽  
Carotid Atherosclerosis ◽  
Vitro Assay ◽  
Carotid Plaques ◽  
Cholesterol Efflux Capacity ◽  
Related Data

Abstract Objectives Lipid profiles appear to be altered in SLE patients due to disease activity and inflammation. Cholesterol efflux capacity (CEC) is the ability of high-density lipoprotein cholesterol to accept cholesterol from macrophages. CEC has been linked to cardiovascular events in the general population and is impaired in SLE patients. The aim of this study was to establish whether CEC is related to subclinical carotid atherosclerosis in SLE patients. Methods The present report is of a cross-sectional study that encompassed 418 individuals: 195 SLE patients and 223 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. Carotid intima-media thickness and carotid plaques were evaluated in SLE patients. A multivariable analysis was performed to study the relationship of CEC to SLE-related data, lipid profile and subclinical carotid atherosclerosis. Results CEC was downregulated in SLE patients [8.1  (4.2) % vs 16.9 (10.4) %, P = 0.004). This occurred independently of traditional cardiovascular risk factors, statin use or other variations in the lipid profile related to the disease. Traditional cardiovascular risk factors, both in patients and controls, and SLE-related data such as activity, severity or damage were not associated with CEC. After multivariable regression analysis including lipid profile–related molecules, CEC was inversely and independently associated with the presence of carotid plaques in SLE patients [odds ratio 0.87 (95% CI: 0.78, 0.97), P = 0.014]. Conclusion CEC is impaired in SLE patients independently of other inflammation-related lipid profile modifications that occur during the disease. CEC is associated with carotid plaques in SLE patients.

scholarly journals General Characteristics and Risk Factors of Cardiovascular Disease among Interstate Bus Drivers

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Raquel Pastréllo Hirata ◽  
Luciana Maria Malosa Sampaio ◽  
Fernando Sergio Studart Leitão Filho ◽  
Alberto Braghiroli ◽  
Bruno Balbi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Lipid Profile ◽  
Cardiovascular Risk Factors ◽  
Sedentary Behavior ◽  
Fasting Blood Glucose ◽  
Young Male ◽  
Hdl Cholesterol ◽  
Bus Drivers ◽  
Male Population

Workers in the transportation industry are at greater risk of an incorrect diet and sedentary behavior. The aim of our study was to characterize a population of professional bus drivers with regard to clinical and demographic variables, lipid profile, and the presence of cardiovascular risk factors. Data from 659 interstate bus drivers collected retrospectively, including anthropometric characteristics, systolic and diastolic blood pressure, lipid profile, fasting blood glucose, meatoscopy, and audiometry. All participants were male, with a mean age of41.7±6.9years, weight of81.4±3.3 kg, and BMI27.2±3.3 Kg/m2; the mean abdominal and neck circumferences were94.4±8.6 cm and38.9±2.2 cm; 38.2% of the sample was considered hypertensive; mean HDL cholesterol was47.9±9.5 mg/dL, mean triglyceride level was146.3±87.9 mg/dL, and fasting glucose was above 100 mg/dL in 249 subjects (39.1%). Drivers exhibited reduced audiometric hearing at 4–8 kHz, being all sensorineural hearing loss. The clinical characterization of a young male population of interstate bus drivers revealed a high frequency of cardiovascular risk factors, as obesity, hypertension, hyperlipidemia, and hyperglycemia, as well as contributing functional characteristics, such as a low-intensity activity, sedentary behavior, long duration in a sitting position, and high-calorie diet, which lead to excessive weight gain and associated comorbidities.

THU0381 MANAGEMENT OF CARDIOVASCULAR COMORBIDITY IN PSORIATIC ARTHRITIS IN THE ROUTINE CLINICAL PRACTICE: A COMPARATIVE STUDY OF METHOTREXATE OR APREMILAST AS MONOTHERAPY AND COMBINED

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 424-425
Author(s):  
N. Barbarroja Puerto ◽  
I. Arias de la Rosa ◽  
C. Torres-Granados ◽  
M. D. C. Abalos-Aguilera ◽  
G. G. Ignacio ◽  
...  
Keyword(s):  
Risk Factors ◽  
Insulin Resistance ◽  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Disease Activity ◽  
Lipid Profile ◽  
Combined Therapy ◽  
Routine Clinical Practice ◽  
Research Support ◽  
Number Of Patients

Background:The presence of cardiovascular disease in psoriatic arthritis (PsA) is of particular concern, as it is considered the leading cause of mortality in PsA. Thus, it is essential to recognize those appropriate therapies that could target this comorbidity, reducing the risk of cardiovascular disease and metabolic alterations.Objectives:To evaluate the efficacy of methotrexate (MTX) and apremilast as monotherapies or in combination, in the clinical manifestations of the disease and the reduction of cardiovascular risk factors in PsA.Methods:Prospective longitudinal study in 30 PsA patients diagnosed according to CASPAR criteria: 10 patients were treated with MTX (12 ± 2,58 mg/week), 10 patients with apremilast (60 mg/day) and 10 were treated with combined therapy for 6 months, recruited in the routine clinical practice at the Reina Sofia Hospital of Cordoba and University Hospital of Jaen, Spain. Clinical and analytical parameters were collected at baseline and after 6 months of treatment: lipid profile (cholesterol, HDL, LDL, TG, ApoA and ApoB), glucose and insulin, body surface area (BSA) affected by psoriasis, number of tender and swollen joints, DAS28, DAPSA, VAS, CRP and ESR.The presence of cardiometabolic risk factors such as metabolic syndrome (MetSyn) was evaluated according to National Cholesterol Education Program (NCEP) adult treatment panel III (ATP III) criteria, meeting 3 of the following characteristics: abdominal obesity (men (>102 cm); women (>88 cm), TG > 150 mg/dL, HDL (men (<40 mg/dL); women (<50 mg/dL), blood pressure > 130/85 mmHg, glucose levels > 110 mg/dL). Insulin resistance (HOMA-IR > 2,5), body mass index (BMI), ApoB/ApoA ratio, atherogenic index (AI) and SCORE (age, gender, cholesterol, HDL, smoking habit and diabetes) were also studied.Results:Apremilast or MTX monotherapies caused a moderate reduction of the clinical inflammatory markers (CRP and ESR) and disease activity (VAS, DAPSA and DAS28) after 6 months of treatment. On the other hand, while apremilast significantly reduced the affected BSA, MTX had no significant effect. All those parameters were more significantly reduced after the combined treatment (MTX+ apremilast).Apremilast monotherapy significantly improved alterations in the lipid profile (reducing cholesterol and LDL levels, ApoB/ApoA ratio and AI), insulin resistance and decreased BMI, thus reducing the number of patients with MetSyn. MTX monotherapy treatment had no positive effect on these parameters. None of the treatments had significant effects on SCORE values.The beneficial effects of apremilast on the lipid profile were mitigated after the combination with MTX. Nevertheless, the number of patients with MetSyn decreased even more after the combined therapy of MTX with apremilast compared to apremilast monotherapy.Conclusion:1) In patients with moderate disease activity, treatment with apremilast monotherapy might have some advantages compared to the MTX monotherapy, since it can decrease the percentage of BSA with psoriasis, the lipid profile alteration, IR and weight, thus improving the cardiovascular risk profile. 2) Combined therapy (MTX+ apremilast) can induce a deeper reduction in the disease activity compared to the monotherapies, maintaining, in turn, the positive effects of apremilast on the cardiovascular risk.Funded by ISCIII (PI17/01316 and RIER RD16/0012/0015) co-funded with FEDER.Disclosure of Interests:Nuria Barbarroja Puerto Grant/research support from: ROCHE and Pfizer., Speakers bureau: ROCHE and Celgene., Iván Arias de la Rosa: None declared, Carmen Torres-Granados: None declared, Maria del Carmen Abalos-Aguilera: None declared, Gómez García Ignacio: None declared, Isabel Añón Oñate: None declared, María José Pérez Galán: None declared, Desiree Ruiz: None declared, Alejandra M. Patiño-Trives: None declared, María Luque-Tévar: None declared, Eduardo Collantes Estevez Grant/research support from: ROCHE and Pfizer, Speakers bureau: ROCHE, Lilly, Bristol and Celgene, Chary Lopez-Pedrera Grant/research support from: ROCHE and Pfizer., Alejandro Escudero Contreras Grant/research support from: ROCHE and Pfizer, Speakers bureau: ROCHE, Lilly, Bristol and Celgene., María Dolores López Montilla Speakers bureau: Celgene

CARDIOVASCULAR RISKS IN OBSTRUCTIVE SLEEP APNEA SYNDROME WITH IMPROVED SASD07 COMPARE TO STARDUST II

2014 ◽  
pp. 77-86
Author(s):  
Anh Tien Hoang ◽  
Thi Y Nhi Nguyen ◽  
Luu Trinh Nguyen ◽  
Thi Hong Diep Phan ◽  
Huu Cat Nguyen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Cardiovascular Risk ◽  
Sleep Apnea ◽  
Sleep Apnea Syndrome ◽  
Hdl Cholesterol ◽  
Control Group ◽  
Positive Correlation ◽  
Obstructive Sleep ◽  
Apnea Syndrome

Background : Sleep Apnea Syndrome (SAS) is a cause of hypertension, increasingcardiovascular risk and cardiovascular disease such as stroke, coronary artery disease, myocardial infarction, arrhythmias, heart failure, increasing the risk of death in patients with heart disease, independent of other causative factors. So far, in Vietnam there are very few studies on Obstructive Sleep Apnea Syndrome (OSAS) and cardiovascular risk factors . Self-making SASD07 is trustly for detecting OSAS with statistical significiant in comparision with StarDustII (gold criteria). Subjects and Methods: Cross sectional study, comparision with control group: 136 peoples (68 in disease group and 68 in control group). Patients were parallelly measured with StarDustII and SASD07 to detect OSAS and find the corellation with cardiovascular risk factors. Results: There is a positive correlation between SBP with the severity of OSAS (r = 0.459, p < 0.001), positive correlation between DBP with the severity of OSAS (r = 0.352, p < 0.003). No statistically significant differences between severe OSAS and fasting blood glucose, cholesterol, HDL Cholesterol, Non - HDL Cholesterol, LDL Cholesterol and TG median (p > 0.05). There is a positive correlation between AHI and neck circumference (r = 0.511, p < 0.001), waist circumference (r = 0.585, p < 0.001), BMI (r = 0.380, p < 0.01). SASD07 diagnostic value of detecting OSAS compared with StarDustII have Kappa = 0.72, (standard error 0.06, p <0.001). Conclusion: The risk factors related to OSAS in our study is neck circumference, waist circumference, systolic blood pressure, diastolic blood pressure. SASD07 have a good value in diagnosing of OSAS compared with polysomnography StarDustII. Key words: Sleep Apnea Syndrome, cardiovascular risk factor, SASD07.

Sign in / Sign up

Export Citation Format

Share Document